Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) is expected to be releasing its earnings data before the market opens on Friday, April 4th. Analysts expect NRx Pharmaceuticals to post earnings of ...

NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a market capitalization of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

MIAMI, March 31, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc ...

(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP) announced Monday that its interventional psychiatry network HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical following ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

The latest price target for NRX Pharmaceuticals (NASDAQ:NRXP) was reported by BTIG on April 2, 2025. The analyst firm set a price target for $18.00 expecting NRXP to rise to within 12 months (a ...

NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and ...